Create PPT on schizophrenia with recent guidelines
Asking for Preferences
Reading File
Searching PubMed
schizophrenia treatment guidelines 2024 2025
Searching the Web
schizophrenia clinical guidelines 2024 2025 APA NICE treatment recommendations
Finding Sources
Reading File
Reading Web Page
schizophrenia treatment guidelines 2025 antipsychotics psychosocial
Reading File
Reading File
Reading File
Reading File
Reading File
Running Command
Writing File
Running Command
Running Command
Your presentation is ready! Here's the download link:
Schizophrenia Comprehensive 2025
Presentation · PPTX
What's inside (28 slides)
The deck uses a professional navy/teal/amber palette with dark title slides and clean content layouts. Here's the full slide structure:
| # | Slide Title |
|---|---|
| 1 | Title Slide |
| 2 | Presentation Outline |
| 3 | Overview & Historical Background (Kraepelin, Bleuler) |
| 4 | Epidemiology & Global Burden (stat boxes: 0.85% prevalence, $155.7B cost) |
| 5 | Etiology & Risk Factors (genetics, neurodevelopmental, environmental) |
| 6 | Neurobiology & Pathophysiology (dopamine, glutamate, serotonin — two columns) |
| 7 | Positive Symptoms (hallucinations, delusions, disorganized thinking, catatonia) |
| 8 | Negative & Cognitive Symptoms (5 A's, MATRICS domains) |
| 9 | DSM-5-TR Diagnostic Criteria (Criteria A–F fully listed) |
| 10 | Differential Diagnosis (table: psychiatric, neurological, autoimmune, toxic) |
| 11 | Subtypes & Related Disorders (schizophrenia spectrum) |
| 12 | Course & Prognosis (good vs. poor prognostic factors, DUP, suicide rate) |
| 13 | First-Generation Antipsychotics (FGAs) — dosing table |
| 14 | Second-Generation Antipsychotics (SGAs) — 10-drug dosing table |
| 15 | Treatment-Resistant Schizophrenia & Clozapine (Lancet Psychiatry 2025 evidence) |
| 16 | Long-Acting Injectables (LAIs) — all formulations |
| 17 | Side Effect Management (table: EPS, TD, NMS, metabolic, QT) |
| 18 | Psychosocial Interventions (CBTp, family therapy, CSC, IPS, ACT) |
| 19 | NICE CG178 (2025) — pharmacological + psychosocial recommendations |
| 20 | APA Guidelines (2020) & VA/DoD CPG (2023) |
| 21 | Recent Evidence 2024–2026 (7 PubMed citations with findings) |
| 22 | Special Populations & Comorbidities (FEP, pregnancy, elderly, substance use) |
| 23 | Monitoring & Follow-Up (parameter table: baseline through annual) |
| 24 | Acute Psychosis & Agitation Management |
| 25 | Emerging Therapies (KarXT/FDA 2024, TAAR1, TMS, digital) |
| 26 | Suicide Risk & Safety (10% lifetime rate, clozapine anti-suicidal effect) |
| 27 | Key Takeaways (8 numbered points on dark background) |
| 28 | References (textbooks, guidelines, PubMed PMIDs) |
Sources used: Harrison's 22E, Goodman & Gilman's, Adams & Victor's 12E, NICE CG178 (2025), APA Practice Guideline (2020), VA/DoD CPG (2023), and 7 recent PubMed publications (2025–2026).
This is a shared conversation. Sign in to Orris to start your own chat.